SLC5A1 and type 2 diabetes mellitus: It also made sense to utilize phlorizin, a dual SGLT2/SGLT1 inhibitor, as a therapeutic option for the treatment of type 2 diabetes (T2D) based on the premise that the induction of glucosuria would reduce the plasma glucose concentration (Figure 1).